Rationale Glutamate and orexin/hypocretin systems are involved in Pavlovian cue-triggered drug seeking. Objectives Here, we asked whether orexin and glutamate interact within ventral tegmental area (VTA) to promote reinstatement of extinguished cocaine seeking in a rat selfadministration paradigm. Methods/results We first found that bilateral VTA microinjections of the orexin 1 receptor (OX1R) antagonist SB-334867 (SB) or a cocktail of the AMPA and NMDA glutamate receptor antagonists CNQX/AP-5 reduced reinstatement of cocaine seeking elicited by cues. In contrast, neither of these microinjections nor systemic SB reduced cocaineprimed reinstatement. Additionally, unilateral VTA OX1R blockade combined with contralateral VTA glutamate blockade attenuated cue-induced reinstatement, indicating that VTA orexin and glutamate are simultaneously necessary for cueinduced reinstatement. We further probed the receptor specificity of glutamate actions in VTA, finding that CNQX, but not AP-5, dose-dependently attenuated cue-induced reinstatement, indicating that AMPA but not NMDA receptor transmission is required for this type of cocaine seeking. Given the necessary roles of both OX1 and AMPA receptors in VTA for cue-induced cocaine seeking, we hypothesized that these signaling pathways interact during this behavior. We found that PEPA, a positive allosteric modulator of AMPA receptors, completely reversed the SB-induced attenuation of reinstatement behavior. Intra-VTA PEPA alone did not alter cueinduced reinstatement, indicating that potentiating AMPA activity with this drug specifically compensates for OX1R blockade, rather than simply inducing or enhancing reinstatement itself. Conclusions These findings show that cue-induced, but not cocaine-primed, reinstatement of cocaine seeking is dependent upon orexin and AMPA receptor interactions in VTA.
Introduction
Conditioned cues are potent triggers of reward seeking in animals and increase relapse risk in abstinent human addicts (Cardinal and Everitt 2004; Robinson and Berridge 2001) . Cues are associated with increased ventral tegmental area (VTA) dopamine cell firing, and concomitant forebrain dopamine release is necessary and sufficient for reward seeking and approach efforts (Berridge and Robinson 1998; Cheer et al. 2007; Fiorillo et al. 2003; Ikemoto and Panksepp 1999; Salamone et al. 2007; Satoh et al. 2003) . Accordingly, VTA is required for cue-induced drug and food seeking (Di Ciano and Everitt 2004; Murschall and Hauber 2006) , but the neurochemical inputs that modulate VTA involvement in conditioned reward seeking are unclear. Orexin and glutamate are two key transmitters involved in cue-induced reward seeking, and it is possible that they act in VTA to modulate this behavior.
Orexin/hypocretin is a hypothalamic peptide neurotransmitter involved in cue-triggered motivation. Lateral hypothalamic (LH) orexin neurons Fos-activate in relation to conditioned place preference Harris et al. 2005) , and systemic injections of the orexin 1 receptor (OX1R) antagonist SB-334867 (SB) attenuate cue-, context-, or stress-induced reward seeking for a variety of drugs of abuse and natural rewards (Boutrel et al. 2005; Cason et al. 2010; Harris et al. 2005; Lawrence et al. 2006; Richards et al. 2008; Smith and Aston-Jones in press; Smith et al. 2009 Smith et al. , 2010 .
In VTA, orexin increases dopamine cell activity and modulates certain reward-seeking behaviors (Espana et al. 2011; Korotkova et al. 2003; Moorman and Aston-Jones 2010; Muschamp et al. 2007; Narita et al. 2006 Narita et al. , 2007 . Intra-VTA microinjections of orexin reinstate extinguished drug seeking (Harris et al. 2005; Wang et al. 2009 ), whereas intra-VTA SB attenuates some types of drug-seeking behaviors (Borgland et al. 2006; Espana et al. 2010; Harris et al. 2007; James et al. 2011; Narita et al. 2006) . These findings indicate that VTA orexin may be involved in learning about and pursuing drugs, especially in response to external stimuli such as Pavlovian cues.
Similar to orexin, glutamate in VTA promotes dopamine cell firing and modulates reward-seeking behavior (Chergui et al. 1993; Geisler et al. 2008; Harris and Aston-Jones 2003; Wang et al. 1994; Zellner and Ranaldi 2010) . AMPA/ NMDA ratios are increased following cocaine exposure, and changes in AMPA subunits, in particular, modulate motivation to self-administer cocaine (Borgland et al. 2004; Choi et al. 2011; Saal et al. 2003; Ungless et al. 2001; White et al. 1995; Zhang et al. 1997) . However, the role played by VTA glutamate in discrete cue-induced relapse to drug seeking has not been well studied. VTA glutamate neurotransmission is necessary for stress-induced reinstatement, as well as cocaine seeking under extinction conditions (Wang et al. 2005; Wise 2009; You et al. 2007) [though see (Nolan et al. 2010) ]. However, as cue-induced reinstatement of extinguished cocaine seeking involves different neural substrates than stressinduced reinstatement or extinction responding Kalivas 2008; Peters et al. 2008; Shaham et al. 2003) , it is important to examine whether VTA glutamate is similarly involved in cue-triggered reinstatement as well.
Recent studies have demonstrated that orexin and glutamate interact at the synaptic level in VTA, and that orexin facilitates glutamate actions on dopamine cell firing. In vitro, orexin potentiates VTA glutamate signaling by increasing the number and function of postsynaptic AMPA and NMDA receptors, as well as glutamate release (Borgland et al. 2009; . In anesthetized animals, orexin also potentiates control of VTA dopamine neurons by prefrontal cortical afferents, further indicating that orexin can amplify concurrent glutamate signaling . However, the degree to which these transmitters interact during goaldirected behaviors has not been explored.
Here, we hypothesized that an interaction between orexin and glutamate in VTA mediates cue-triggered cocaine seeking in a self-administration/reinstatement model of relapse. We found that OX1R and AMPA transmission in VTA are simultaneously necessary for cues, but not cocaine, to trigger drug seeking. We also show that when VTA OX1R transmission is antagonized, facilitating endogenous AMPA transmission with the positive allosteric modulator PEPA restores cueinduced reinstatement behavior to control levels. These findings point to a synergistic interaction of VTA OX1 and AMPA receptor signaling that is required for drug-associated stimuli to trigger relapse in addiction.
Methods

Subjects
Male Sprague Dawley rats (n0141; arrival weight 250-300 g; Charles River) were single-or double-housed under a reverse 12:12 h light cycle in a standard tub cage with corncob bedding and ad lib food and water. All procedures were approved by the Medical University of South Carolina's Institutional Animal Care and Use Committee and conducted according to specifications of the Guide for the Care and Use of Laboratory Animals (2011).
Surgery
Intracranial cannulae
Animals were anesthetized with ketamine/xylazine (56.5/ 8.7 mg/kg) and received the non-opioid analgesic meloxicam (1 mg/kg). Bilateral 23-ga stainless steel guide cannulae were implanted 2 mm above VTA (n076) or nearby control sites (n039) with a stereotaxic device (coordinates for VTA (relative to bregma): AP0−5.2 to −6.2; ML0+2.0 to 2.2; DV0−7.0 to −7.2). Cannulae were affixed to the skull with screws and dental cement and occluded with 28-ga stainless steel stylets.
Jugular catheters
In the same surgery, chronic indwelling catheters were inserted into the right jugular vein and exited the body via a port between the scapulae. Animals received prophylactic i.v. cefazolin (10 mg) and heparin (10 U) daily starting 3 days after surgery and continuing throughout self-administration. Rats receiving systemic SB (n026) received jugular catheters only. Animals were allowed to recover for 1 week prior to selfadministration training.
Drugs
Cocaine
Cocaine HCl (NIDA, Research Triangle Park, NC) was dissolved in 0.9% sterile saline.
Orexin antagonist
For systemic administration, the OX1R antagonist SB-334867 [SB; purchased from Tocris (Ellisville, MO), or generously donated by Eli Lilly (Indianapolis, IN)] was suspended in 2% dimethylsulfoxide (DMSO) and 10% 2-hydroxypropyl-betacyclodextrin (Sigma; St. Louis, MO) in sterile water; all doses were given in a volume of 4 ml⁄kg (i.p.). A 30-mg/kg SB dose was chosen based upon our previous finding that this dose abolished cue-induced reinstatement ). For intracranial microinjections, SB was obtained from Tocris and suspended in artificial cerebrospinal fluid with agitation and sonification (ACSF; 1 mM). This concentration of SB was chosen as a relatively low dose based on previous intracranial injection studies (Borgland et al. 2006; Espana et al. 2010; Harris et al. 2007; James et al. 2011) . When SB was compared to or mixed with PEPA, 2% DMSO was added to drug and vehicle preparations.
Glutamate antagonists
The AMPA antagonist CNQX (0.7 and 0.35 mM) and the NMDA antagonist AP-5 (1.6 and 0.8 mM) were obtained from Sigma and dissolved in ACSF. These doses were chosen based on previous VTA microinjection studies, and they are about 10× higher concentrations than those used for in vivo electrophysiology in anesthetized preparations and over 100× higher concentrations than used in slice physiology experiments (Georges and Aston-Jones 2002; Harris and AstonJones 2003; Harris et al. 2004; Marinelli et al. 2005; Riegel and French 2002) . The higher dose of each antagonist was used for the CNQX/AP-5 cocktail.
AMPA allosteric enhancer
PEPA (Tocris) enhances glutamate binding at AMPA receptors and decreases AMPA desensitization, potentiating functional effects of endogenous glutamate release in vitro and in vivo (Ahmed et al. 2010; LaLumiere et al. 2010; Sekiguchi et al. 1997; Yamada et al. 2009 ). PEPA was dissolved in 2% DMSO and diluted with ACSF to 0.25 or 0.5 mM, less than 30 min prior to microinjection. These doses were chosen based on previous microinjection studies using PEPA (LaLumiere et al. 2010; Zushida et al. 2007 ). For PEPA+SB microinjections, both drugs were mixed into a cocktail shortly before microinjection.
Handling and microinjections
Animals were handled for 5 min each day for at least 3 days prior to beginning self-administration training. Before the first microinjection, an injector extending 2 mm past the end of the cannula into the brain structure of interest was inserted to habituate animals to microinjection procedures. Five minutes prior to behavioral testing, microinjections were administered through a 28-ga injector (2 mm past guide cannulae) in a 0.3-μl volume over 70 s by automated syringe pump, and injectors were left in place for 1 additional min to allow diffusion away from injection site. No animal received more than five total microinjections in any experiment.
Behavioral training
Med-Associates experimental chambers (St. Albans, VT) were equipped with two retractable levers with white lights above them, a red houselight, and a tone generator. Intravenous cocaine was administered via a pump located outside a soundattenuating box. Rats received 10 daily 2-h cocaine selfadministration sessions (>10 cocaine infusions/day, 0.2 mg/ 50 μl infusion). Pressing one lever (active lever; fixed ratio 1 schedule) yielded a 3.6-s cocaine infusion, 2.9-kHz tone, and light presented above the active lever. A 20-s timeout period (signaled by turning off the houselight) followed, during which additional lever presses yielded nothing. Presses on the other lever (inactive lever) had no consequences at any time. By the end of self-administration, animals received 35.7±1.3 (mean±SEM) cocaine infusions/ day. No differences in total cocaine intake between experimental groups or VTA vs. control site cannula groups were found.
Animals next received at least 7 days of extinction training, during which active lever presses yielded neither cocaine nor tone/light cues. On the first day of extinction, active and inactive lever presses increased over self-administration levels (active lever: t 63 024.2; inactive lever: t 63 06.8, ps<0.001), but pressing decreased significantly over the next 6 days of extinction training (Fig. 1) . Rats received extinction training until they pressed <25 times on the active lever for 2 or more consecutive days. Between cue-induced or cocaine-primed reinstatement sessions, animals received at least 2 additional extinction training days, until they returned to extinction criterion. No differences in the number of extinction days to criterion were found between animals with VTA or control site cannulae or between experimental groups.
Reinstatement testing
Cue-induced reinstatement
Animals received three cue-induced reinstatement tests after reaching extinction criterion. During these 2-h sessions, active lever presses yielded the tone/light presentations previously paired with cocaine, but no cocaine. As in self-administration training, each cue presentation was followed by a 20-s timeout period where lever presses were recorded, but yielded no additional cue presentations. Cue-induced reinstatement testing was completed first, followed by cocaine-primed reinstatement testing, in order to prevent potential effects of non-contingent cocaine injections on cue-induced reinstatement behavior (Feltenstein et al. 2009; Kippin et al. 2006; Rogers et al. 2008; See 2009 ).
Cocaine-primed reinstatement
Animals were injected with cocaine (10 mg/kg; i.p.) immediately prior to being placed in the experimental chamber for a 2-h session. Active and inactive lever presses were recorded, but did not result in cue presentations or cocaine.
Experimental manipulations
Effects of orexin and glutamate antagonists on cue-induced reinstatement
Five min prior to each test, rats received bilateral microinjections (in counterbalanced order) of 0.3-μl ACSF vehicle and two of the following: bilateral SB (1 mM; VTA n023; control sites n017), bilateral CNQX/AP-5 cocktail (0.7/1.6 mM; VTA n022; control sites n014) and unilateral SB+contralateral CNQX/AP-5 (VTA n016; control sites n010). All rats received three total cue-induced reinstatement sessions. To examine the relative contributions of VTA NMDA vs. AMPA receptors in cue-induced reinstatement, separate groups of animals received vehicle either CNQX (0.7 and 0.35 mM; VTA n07) or AP-5 (1.6 and 0.8 mM; VTA n09; control site n01) in counterbalanced order prior to cue-induced reinstatement tests.
Effects of orexin and glutamate antagonists on cocaine-primed reinstatement
A subset of the animals tested for cue-induced reinstatement also received cocaine-primed reinstatement tests after bilateral microinjections (in counterbalanced order) of vehicle and one of the following (at the same concentrations and volumes as previously discussed): bilateral SB (VTA n015, control sites n014), bilateral cocktail of CNQX/AP-5 (VTA n015, control sites n04), bilateral CNQX alone (VTA n04), and bilateral AP-5 alone (VTA n04; control sites n01). No animals received more than five intra-VTA microinjections in total.
Systemic SB effects on cocaine-primed reinstatement
Vehicle or SB (10 mg/kg, n09; or 30 mg/kg, n017) was injected (i.p.) in counterbalanced order 30 min prior to each of two cocaine priming reinstatement test sessions per animal.
Effects of SB and PEPA on cued reinstatement
A separate group of animals was assigned to receive, in counterbalanced order, 0.3 μl of 2% DMSO ACSF vehicle and two of the following prior to cue reinstatement tests: SB alone (1 mM; VTA n020; control sites n010), a cocktail of 1-mM SB+0.25 mM PEPA (VTA n06; control sites n08), 1-mM SB+0.5 mM PEPA (VTA n018; control sites n08), and 0.5 mM PEPA alone (VTA n013; control sites n03). Some animals also received vehicle and 0.5 mM PEPA alone under extinction conditions (VTA n09; control sites n06).
Histology
Following behavioral testing, animals were deeply anesthetized with ketamine/xylazine, and brains were removed, frozen, sectioned at 60 μm on a cryostat, and counterstained with neutral red. Cannula sites in and around VTA were compared with Paxinos and Watson (2007) to reconstruct microinjection sites (Fig. 5) . Animals with both microinjection sites within the borders of VTA were considered hits, and animals with one or both injection sites in adjacent brain regions were considered control site injections.
Statistics
Reinstatement after vehicle microinjections was verified with paired sample t-tests comparing the average of the last 2 days of extinction pressing to pressing on vehicle 
Day of Extinction
Inactive VTA Microinjection Fig. 1 Simultaneous VTA orexin and ionotropic glutamate transmission is necessary for cue-induced reinstatement of cocaine seeking. Day of self-admin: lever presses (active and inactive) and cocaine infusions (with cue presentations) are shown for days 8-10 of self-administration. Day of extinction: lever presses during the first 7 days of extinction (no cocaine, no cues) are shown. Cue-induced reinstatement: cue-induced reinstatement behavior is shown after VTA microinjections of bilateral vehicle (Veh), bilateral orexin blockade with SB-334867 (SB; 1 mM), bilateral glutamate blockade with a microinjection of a cocktail of the NMDA/AMPA antagonists CNQX/AP-5 (0.7 and 1.6 mM), or unilateral VTA SB with simultaneous contralateral VTA CNQX/AP-5 cocktail (Contra). Inactive lever presses on reinstatement days are shown with black bars. reinstatement days. Mixed model ANOVAs tested effects of drug (between-subjects factor) on active and inactive lever pressing (within-subject factor) to examine effects on reinstatement of intra-VTA: (a) vehicle, (b) bilateral SB (1 mM), (c) bilateral AP-5/CNQX (0.7/1.6 mM), and (d) unilateral SB (1 mM) with simultaneous contralateral AP-5/CNQX (0.1/1.6 mM) (Fig. 1) . Effects of PEPA on reinstatement, with or without concurrent SB, were also tested with a mixed ANOVA, including a between-subjects factor of drug (vehicle, SB alone, SB+0.25 mM PEPA, SB+0.5 mM PEPA, 0.5 mM PEPA alone), and the within-subjects factor of lever (active, inactive). Fisher's least significant difference posthoc tests were used to compare cocaine seeking after each drug to vehicle. Mixed ANOVAs were used because animals received three cue-induced reinstatement sessions (of the four or five possible conditions, depending on the experiment), which precluded the use of repeated-measures ANOVA to analyze across all conditions. Effects of PEPA on extinction responding were tested with ANOVAs, including two within-subjects factors: drug (vehicle vs. PEPA) and lever (active, inactive). Repeated-measures ANOVAs (two within-subjects factors: drug×lever) were also used to examine the effects of intra-VTA CNQX (0, 0.35, and 0.7 mM) or AP-5 (0, 0.8, and 1.6 mM) on cue-induced reinstatement. For repeatedmeasures ANOVAs, Bonferroni-corrected t-test posthocs were employed. To examine effects of systemic SB on cue-induced reinstatement, a mixed model ANOVA tested effects of drug (0 and 10 or 30 mg/kg; between-subjects factor) on active and inactive lever pressing (within-subjects factor).
Results
Simultaneous VTA orexin and glutamate transmission is necessary for cue-induced reinstatement After vehicle microinjections into VTA animals robustly reinstated active lever, but not inactive lever, pressing for cocaine cues compared to the average of the last 2 extinction training days ( Fig. 1 ; active lever: t 34 06.2, p<0.001; inactive lever: n.s.). However, VTA microinjections of bilateral SB, bilateral CNQX/AP-5, or contrahemispheric SB and CNQX/AP-5 all reduced active lever pressing to less than half of vehicle reinstatement levels ( Fig. 1 ; drug×lever interaction: F(3,92)0 6.6, p<0.001; LSD posthocs for drug effects-veh vs.: SB: p< 0.001; CNQX/AP-5: p<0.01; contralateral CNQX/AP-5 and SB: p00.02). In contrast, inactive lever presses were not significantly affected by drug microinjections compared to vehicle day.
Neither VTA OX1R nor glutamate receptor signaling is necessary for cocaine-primed reinstatement In vehicle-treated animals, cocaine priming injections robustly reinstated pressing on the active lever, but not the inactive lever compared to prior extinction days (active lever: t 22 05.5, p<0.001, inactive lever: n.s.). Systemic administration of SB at 10 or 30 mg/kg did not affect cocaine-primed reinstatement of pressing on either the active or inactive lever (Fig. 2) , whereas previous studies found that 30-mg/kg SB completely blocked cue-induced reinstatement of cocaine seeking ).
Similarly, intra-VTA microinjections of neither SB nor a CNQX/AP-5 cocktail affected cocaine-primed reinstatement (Fig. 2) , though the same doses of these antagonists attenuated cue-induced reinstatement (Fig. 1) . Inactive lever presses were also unaffected by bilateral intra-VTA orexin or glutamate antagonists after a cocaine prime (Fig. 2) . Together, these results reveal specificity for VTA orexin and glutamate involvement in cue-induced vs. cocaine-primed reinstatement.
VTA AMPA, but not NMDA, transmission is necessary for cue-induced reinstatement Next, we compared effects of AMPA vs. NMDA antagonists on cue-induced reinstatement (Fig. 3) . The AMPA antagonist CNQX dose-dependently attenuated cue-induced reinstatement, as compared to vehicle (drug×lever interaction: F(2,12)04.7, p<0.05; 0.7 mM: t 6 02.5, p<0.05; 0.35 mM: n.s.). In contrast, the NMDA antagonist AP-5 did not affect cue-induced reinstatement at either dose. Neither 0.7 mM Fig. 2 Neither VTA orexin nor ionotropic glutamate transmission is necessary for cocaine-primed reinstatement. Extinction (left bar): the average of the last 2 days of extinction responding immediately before reinstatement tests is shown for comparison with cocaine-primed reinstatement. Systemic SB injection: cocaine-primed reinstatement behavior is shown after systemic injections of vehicle or SB-334867 (10 or 30 mg/kg, i.p.). VTA microinjection: cocaine-primed reinstatement behaviors are shown after bilateral intra-VTA SB (1 mM) or CNQX/AP-5 (0.7/1.6 mM). Inactive lever presses on reinstatement test days are shown with black bars CNQX nor 1.6 mM AP-5 affected cocaine-primed reinstatement in a small subset of animals, as expected given the lack of effect of the drug cocktail on cocaine-primed reinstatement. These findings indicate that simultaneous AMPA and OX1R transmission in VTA are required for cues to trigger maximum reinstatement of cocaine seeking.
Potentiation of endogenous glutamate signaling at AMPA receptors compensates for orexin antagonism and restores reinstatement
In a separate group of animals, we asked whether potentiating endogenous glutamate signaling via administration of the allosteric AMPA receptor enhancer PEPA would overcome SB-induced attenuation of cue-induced reinstatement (Fig. 4) . Again, we found cue-induced reinstatement of cocaine seeking following VTA vehicle injections, as compared to extinction levels (t 23 04.6, p<0.001). Bilateral VTA SB (1 mM) once again reduced reinstatement to half of vehicle levels, but coadministration of 0.5 mM (but not 0.25 mM) PEPA with SB in a cocktail microinjection rescued cue-induced reinstatement to vehicle levels (drug×lever interaction: F(3,64)04.7, p<0.01, veh vs. SB: p<0.01; SB alone vs. SB+0.5-mM PEPA: p<0.05; SB alone vs. SB+0.25-mM PEPA: n.s. ; Fig. 4 ). Reinstatement was not statistically different after vehicle or SB+0.5-mM PEPA microinjections, demonstrating a complete reversal of intra-VTA SB effects. PEPA alone did not potentiate cue-induced reinstatement over vehicle levels (vehicle vs. 0.5-mM PEPA: n.s.). In addition, the recovery of SBattenuated reinstatement by 0.5-mM PEPA was not due to a simple additive increase in cocaine seeking, as PEPA alone did not drive reinstatement when given in an extinction test (no main effect of drug or drug×lever interaction). These findings point to a functional interaction of orexin and glutamate inputs in VTA in triggering motivation specifically in response to drug-associated cues.
VTA is a critical site for orexin and glutamate promotion of reinstatement
In contrast to the reliable attenuation of cue-induced reinstatement observed with bilateral SB, CNQX, or contrahemispheric SB and glutamate antagonist microinjections into VTA, similar unilateral or bilateral microinjections outside VTA into adjacent structures such as the caudal lateral hypothalamus (n08), substantia nigra (n04), mammillary nucleus (n05), or red nucleus (n09) were ineffective (Fig. 5 , bilateral extra-VTA placements represented with green/dark gray dots). Similarly, PEPA did not significantly affect reinstatement when injected outside VTA, with or without SB co-injection. No consistent differences in drug effects at the different individual control sites were observed. In animals with a unilateral VTA cannula (and the other cannula in a nearby control structure; n018), microinjected drugs also had no significant effects on cued reinstatement (Fig. 5 , yellow/light gray dots; no effect of SB, CNQX/AP-5, or contralateral SB and CNQX/AP-5), indicating that bilateral blockade of orexin or glutamate receptors is required to reduce cue-induced reinstatement. Therefore, VTA is likely to be the main locus for the observed effects of orexin and glutamate receptor drugs on cued reinstatement.
Discussion
Here, we provide the first functional evidence that simultaneous ventral tegmental area (VTA) orexin and glutamate signaling is necessary for cue-induced relapse to drug seeking and that orexin acts to facilitate VTA AMPA responses to cuerelated glutamate inputs. We found that bilateral VTA injection of the OX1R antagonist SB, the AMPA antagonist CNQX, or a cocktail of the AMPA/NMDA antagonists CNQX/AP-5 attenuates cue-induced reinstatement of extinguished cocaine seeking. In contrast, none of these manipulations affect cocaine-primed reinstatement. Intra-VTA AP-5 alone failed to affect either cue-induced or cocaine-primed reinstatement, indicating that AMPA, not NMDA receptors, is the critical signaling mechanism for VTA glutamate modulation of cueinduced reinstatement. Unilateral VTA OX1R blockade and simultaneous contrahemispheric VTA glutamate blockade also attenuates cue-induced reinstatement, indicating that simultaneous orexin and glutamate transmission in VTA is necessary. Finally, we found that enhancing VTA responses to endogenous glutamate signals with the AMPA allosteric modulator PEPA compensates for antagonizing OX1Rs by restoring cocaine seeking to control levels, although it did not elicit reinstatement on its own. These results show that an interaction of VTA OX1 and AMPA receptor signaling is necessary for reinstatement of cocaine seeking elicited by cues, but not a cocaine prime.
VTA orexin is necessary for cue-induced but not cocaine-primed reinstatement
Orexin plays a crucial role in some, but not all, types of reward seeking. Previous studies showed that OX1R signaling is necessary for reward seeking triggered by cues, contexts, or stressors. Systemic administration of SB reduces discrete cueand/or context-induced reinstatement of cocaine, ethanol, heroin, and food seeking (Cason et al. 2010; Lawrence et al. 2006; Smith and Aston-Jones in press; Smith et al. 2009 , and stress-induced reinstatement of cocaine and ethanol seeking (Boutrel et al. 2005; Richards et al. 2008) . Systemic SB also blunts cocaine self-administration under progressive ratio, but not fixed ratio-1, schedules, indicating that orexin is specifically involved in the motivational and cue-driven aspects of cocaine seeking, but not in primary cocaine reinforcement (Borgland et al. 2009; Espana et al. 2010; Smith et al. 2009 ). Here, we found that reinstatement of cocaine seeking evoked by a cocaine prime is unaffected by microinjection sites outside the borders of the VTA are represented, from animals with unilateral (yellow/light gray dots) or bilateral (green/ dark gray dots) cannula placements in nearby structures. For VTA and control site animals, bilateral placements were collapsed into a unilateral view for presentation [adapted from Paxinos and Watson (2007) ]. Control site microinjections ineffective: cue-triggered reinstatement data for animals with unilateral or bilateral cannula placements outside the VTA are shown, after microinjections of vehicle (Veh), SB-334867 (SB; 1 mM), CNQX/AP-5 (0.7/1.6 mM), or contralateral SB and CNQX/AP-5 (Contra). Inactive lever presses are shown with black bars systemic SB, indicating that OX1Rs are also unnecessary for the priming properties of cocaine (Fig. 2) . Taken together, these findings show that orexin is specifically involved in cocaine seeking triggered by external stimuli (e.g., cues, contexts, stressors).
The current results also demonstrate that VTA is a critical site for orexin's role in cue-triggered drug seeking. Previous studies found that intra-VTA SB reduces acquisition of drug place preferences, cocaine sensitization, and motivation to work for cocaine (Borgland et al. 2006; Espana et al. 2010; Harris et al. 2007; Narita et al. 2006 ). In addition, James et al. (2011) recently demonstrated that a high concentration of SB (~20× higher than used here) injected unilaterally in VTA attenuates reinstatement of cocaine seeking elicited by a discriminative stimulus cue, without affecting locomotor activity. Here, we show that selective OX1R blockade in VTA prevents discrete cocaine-associated cues from serving as effective conditioned reinforcers, as bilateral VTA injections of SB reduced cue-induced reinstatement of cocaine seeking to half of vehicle levels (Fig. 1) . In contrast, SB injections nearby, but outside the borders of VTA, failed to affect cocaine seeking; therefore, SB effects are not likely to have been due to diffusion of the drug to adjacent structures (Fig. 5) . Importantly, unilateral VTA SB (or glutamate antagonists) did not affect cue-triggered reinstatement, indicating that VTA orexin/glutamate transmission in at least one hemisphere is sufficient for maximal reinstatement to occur.
VTA glutamate is also required for cue-induced but not cocaine-primed reinstatement
We also found that VTA microinjections of a relatively low dose of the specific AMPA antagonist CNQX attenuated the ability of cues to reinstate cocaine seeking (Fig. 3) . In contrast, the specific NMDA antagonist AP-5 did not affect cue-induced reinstatement on its own, nor did it potentiate CNQX effects on cue-induced reinstatement. Instead, NMDA receptors in VTA may be required for learning about rewards but not for generating motivation based on prior learning, consistent with the present results (Harris et al. 2004; Ranaldi et al. 2010; Zellner et al. 2009 ). Bossert et al. (2004) previously demonstrated an important role for VTA glutamate release in context-induced reinstatement of heroin seeking, and another report showed that the non-selective ionotropic glutamate antagonist kynurenic acid in VTA blocked reinstatement of cocaine seeking by cocaine+ discrete cues (Sun et al. 2005 ). In addition, You et al. (2007) found that low concentrations of either CNQX or AP-5 (both at 0.1 mM) blocked cocaine seeking in early extinction, although a later paper by Nolan et al. (2010) failed to replicate this effect of AMPA antagonism with NBQX, a drug with lower affinity for the glycine binding site on the NMDA receptor than CNQX. Here, we demonstrate that VTA AMPA blockade with CNQX dose-dependently attenuated cueinduced cocaine seeking, whereas even relatively high concentrations of the NMDA antagonist AP-5 (up to 1.6 mM) failed to do so. The doses of AMPA and NMDA antagonists used here are the same or higher than those previously shown, in VTA, to block drug seeking (Harris and Aston-Jones 2003; Harris et al. 2004; You et al. 2007) and to block increases in PFC or NAc dopamine caused by handling stress, systemic nicotine injection, or glutamate agonist co-infusion Fu et al. 2000; Svensson et al. 1998; Westerink et al. 1998 ). The present findings therefore indicate that the lack of effect observed for NMDA blockade on cue-induced or cocaine-primed reinstatement is not likely due to insufficient dosing. Instead, although cocaine seeking in early extinction requires both AMPA and NMDA transmission in VTA (You et al. 2007 ), cue-induced reinstatement of cocaine seeking appears to be dependent upon AMPA transmission alone in VTA.
Like SB, intra-VTA glutamate antagonists failed to reduce cocaine-primed reinstatement at the same doses at which they markedly reduced cue-induced cocaine seeking, indicating a specific role for VTA glutamate in appetitive responses to drugpaired conditioned stimuli. This contrasts with previous studies showing attenuated cocaine-primed reinstatement following intra-VTA administration of kynurenic acid or a high dose of CNQX (~10× higher than the high dose here), though a similar CNQX dose as used here did not affect primed reinstatement (Schmidt et al. 2009; Wise et al. 2008 ). In addition, Rebec and colleagues found that that intra-VTA kynurenic acid blocked cocaine+cue-induced reinstatement, and the glutamate release inhibitor LY-379268 blocked cocaine-primed reinstatement (Lu et al. 2011; Sun et al. 2005) . These previous results may be explained by an attenuation of baseline VTA firing, rather than a specific blockade of reinstatement-related glutamate inputs. High-dose glutamate antagonists can reduce tonic and phasic firing rates of VTA dopamine cells and concomitant forebrain extrasynaptic dopamine levels (Chergui et al. 1993; Christoffersen and Meltzer 1995; Sombers et al. 2009; Takahata and Moghaddam 2000) . Because dopamine reuptake blockade by cocaine is impulse dependent, strongly decreased tonic firing of dopamine neurons by these high-dose treatments might limit cocaine's ability to increase extracellular dopamine and thus decrease drug seeking primed by cocaine (Nomikos et al. 1990; Sombers et al. 2009 ). In the current studies, cocaineprimed reinstatement was not affected by the same doses of glutamate (and orexin) antagonists that robustly attenuated cueinduced reinstatement, indicating that these doses of antagonists effectively interfered with VTA's role in cue-induced drug seeking, but likely spared tonic dopamine cell activity necessary for cocaine-primed relapse.
It is unlikely that the reduction in reinstatement behavior observed after orexin and/or glutamate receptor antagonism can be attributed to general effects on locomotion. First, none of the manipulations reduced pressing on an inactive control lever. Second, a previous report also showed that much higher doses of SB microinjected into VTA failed to affect spontaneous locomotor activity (James et al. 2011) . Further, a relatively high systemic dose of SB (30 mg/kg) failed to affect lever pressing for food pellets, suggesting a lack of general locomotor suppression (LeSage et al. 2010 ). Higher systemic doses of SB (up to 30 mg/kg) only modestly reduce activity in a locomotor chamber and have no effect on some types of lever pressing, including cocaine-induced reinstatement (Fig. 2) or cocaine self-administration ).
A synergistic interaction between VTA glutamate and orexin transmission Previous work has shown that orexin inputs to VTA can enhance dopamine cell activity by potentiating their responses to glutamate inputs. VTA recordings in vitro show that application of orexin promotes synaptic insertion of NMDA receptors and enhanced AMPA and NMDA responses to glutamate agonists (Borgland et al. 2006) . Following a history of cocaine or palatable food self-administration, orexin has the additional effect of amplifying presynaptic glutamate release (Borgland et al. 2009 ). Electrophysiology studies in vivo also indicate that orexin facilitates glutamatergic control of VTA dopamine neurons, as a low concentration of intra-VTA orexin A potentiates dopamine cell firing evoked by stimulation of putatively glutamatergic inputs from medial prefrontal cortex .
Given these previous reports, as well as the classical role for VTA dopamine neurons in reward seeking and the present findings that both VTA orexin and glutamate are necessary for cue-induced cocaine seeking, we hypothesized that simultaneous orexin and glutamate transmission in VTA promotes cue-triggered reinstatement of extinguished cocaine seeking. Therefore, we first asked whether orexin and glutamate are simultaneously necessary for cue-induced reinstatement. We found that blocking ionotropic glutamate receptors in one VTA, while concurrently blocking OX1Rs in the contralateral VTA, attenuates cue-induced reinstatement. This indicates that neither VTA orexin nor glutamate inputs alone are sufficient for cue-induced reinstatement to occur; instead, maximal cocaine seeking requires both. However, this experiment does not directly test the interaction of orexin and glutamate, but instead confirms that simultaneous orexin and glutamate inputs to VTA are necessary for cues to elicit maximal cocaine seeking.
Therefore, we further tested the hypothesis that orexin potentiates VTA responses to cue-related glutamate by employing the allosteric AMPA receptor modulator PEPA, which prolongs endogenous glutamate-induced AMPA activation by preventing receptor desensitization and increasing glutamate binding affinity (Kessler and Arai 2006; Sekiguchi et al. 1997) . When injected into infralimbic cortex, PEPA potentiates extinction of fear and drug memories, showing that PEPA can functionally promote endogenous glutamate transmission in vivo (LaLumiere et al. 2010; Lalumiere et al. 2012; Zushida et al. 2007 ). Here, we report the first usage of PEPA to examine a functional interaction between AMPA and another receptor system. We found that intra-VTA PEPA reverses effects of OX1R blockade and returns cue-triggered reinstatement to control levels. This suggests that VTA orexin normally potentiates activity at AMPA receptors to drive cue-triggered cocaine seeking, but when orexin is blocked by SB, reinstatement can be rescued by enhancing AMPA activity via a completely different mechanism. Importantly, we found that intra-VTA PEPA alone does not induce reinstatement. This is likely due to the fact that PEPA is an allosteric modulator of AMPA receptors and is relatively ineffective in the absence of significant local glutamate release. Therefore, PEPA has no effect on cocaine seeking during late extinction, when there is no cueinduced VTA glutamate release. However, PEPA alone also fails to enhance cue-induced reinstatement above control levels, indicating a potential ceiling effect for glutamate's impact on VTA cell firing and/or cue-triggered motivation in the presence of intact orexin neurotransmission. It is only after OX1R blockade that co-administered PEPA has an effectcompletely restoring cue-induced reinstatement. These data, in conjunction with related previous findings, strongly point to a crucial interaction between VTA orexin and AMPA receptor signaling that promotes cue-triggered motivation. Previously, Wang et al. (2009) showed that intra-VTA orexin A administration induces reinstatement of cocaine seeking, and this effect is attenuated by concurrent administration of the non-selective ionotropic glutamate antagonist kynurenic acid. The present data suggest that this effect was very likely AMPA mediated. Together, these findings support the hypothesis that orexin potentiation of VTA AMPA signaling is crucial for reinstatement of cocaine-seeking behavior.
We propose that orexin enhances VTA dopamine cell responses to glutamate inputs that convey stimulus information required for transforming cues into potent triggers of cocaineseeking behavior. These glutamate inputs to VTA may arise from prefrontal cortex, hypothalamus, or other afferents (Geisler et al. 2007; You et al. 2007; Zellner and Ranaldi 2010) . We further propose that concurrent cue-related orexin release in VTA [likely originating from lateral portions of the hypothalamic orexin field (Harris and Aston-Jones 2006)] enhances responsiveness of VTA neurons to these glutamate inputs via AMPA receptor recruitment, promoting the incentive salience of encountered cues and leading to relapse (AstonJones et al. 2009; Borgland et al. 2006; Moorman and AstonJones 2010) . This synergistic interaction of orexin and glutamate in VTA may provide a novel pharmacological target for reducing cue-triggered cravings and relapse in human addicts.
